Endurant Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Endurant Capital Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-49,899	Closed	-$6.22M	–	73
2017 Q4	$6.22M	Buy	49,899 +11,100	+29%	+$1.42M	1.9%	21
2017 Q3	$5.2M	Sell	38,799 -7,200	-16%	-$938K	1.58%	23
2017 Q2	$5.78M	Buy	45,999 +27,549	+149%	+$3.32M	1.63%	26
2017 Q1	$2.2M	Sell	18,450 -6,200	-25%	-$725K	0.71%	41
2016 Q4	$2.65M	Buy	24,650 +18,500	+301%	+$2.01M	1.1%	36
2016 Q3	$709K	Sell	6,150 -10,150	-62%	-$1.16M	0.26%	61
2016 Q2	$1.67M	Buy	+16,300	New	+$1.74M	0.56%	47

Other funds holding BBH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

BRM

Boston Research & Management Manchester, Massachusetts $421M AUM 16.18% 1-Year Est. Return

Endurant Capital Management's BBH Position: Q1 2018 in Review

Endurant Capital Management sold out of VanEck Biotech ETF (BBH) in Q1 2018, closing a stake of 49,899 shares — an estimated $6.22M sold.

Endurant Capital Management first reported a position in BBH in Q2 2016 and held it in 7 quarters. The position peaked at $6.22M in Q4 2017. 82 funds tracked by Wall St. Rank hold BBH as of Q1 2018.

Endurant Capital Management reported no remaining VanEck Biotech ETF position as of Q1 2018 after selling out during the quarter.
Endurant Capital Management sold 49,899 VanEck Biotech ETF shares in Q1 2018, an estimated $6.22M.
Endurant Capital Management first reported a position in VanEck Biotech ETF in Q2 2016 and held it in 7 quarters.
Endurant Capital Management's VanEck Biotech ETF position peaked at $6.22M in Q4 2017.
82 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2018.

Based on Endurant Capital Management's 13F filing for Q1 2018, filed 15 May 2018.